Express News | Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $49
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments,
Halozyme Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
Halozyme Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
The Price Is Right For Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) price-to-earnings (or "P/E") ratio of 21.1x might make it look like a sell right now compared to the market in the United States, where around half of
Top Medical Stocks to Buy for Growth & Performance
The higher the broader indexes go, the more conscious investors will be of investments that may offer defensive safety.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This Is How Much It'd Be Worth Now
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 520.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 28, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 28, with a total market value of approximately $520.4K
Halozyme Therapeutics(HALO.US) Officer Sells US$1.56 Million in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBrosse Nicole sold 30,000 shares of common stock on Jun 26, 27, 28, 2024 at an average price of $51.931 for a total value of $1.56 million.Source: Announceme
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 519.34K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 27, with a total market value of approximately $519.34
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 518.2K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 26, with a total market value of approximately $518.2K
Halozyme Therapeutics Is Maintained at Buy by Benchmark
Halozyme Therapeutics Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $60
Benchmark Co. analyst Robert Wasserman maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and adjusts the target price from $50 to $60.According to TipRanks data, the analyst has a success
Express News | Halozyme Therapeutics Inc : Benchmark Raises Target Price to $60 From $50
Roche's OCREVUS SC Administration Approved by European Commission
Express News | Halozyme Announces Roche's Ocrevus® Sc With Enhanze® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics (NASDAQ:HALO) Shareholder Returns Have Been Stellar, Earning 193% in 5 Years
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish.The following table provides a quick overvi
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $65
H.C. Wainwright analyst Mitchell Kapoor maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate o
Express News | HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target